NexImmune Raises Gross Proceeds of $126.5M in Upsized IPO after Full Exercise of Underwriters’ Option to Purchase Additional Shares Feb 23, 2021, 08:00 ET ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/…
Read More
GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate…
With more than 25 years of clinical development leadership experience at companies such as Celgene and Kite Pharmaceuticals, Dr. Knight will now lead the clinical development of NexImmune’s novel immunotherapy…
Zeldis formerly served as Celgene CMO and CEO of Celgene Global Health Weber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientist Both will help NexImmune advance…
Initial data demonstrate early signs of safety, tolerability and robust immune responses in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT) GAITHERSBURG, Md., Dec….
GAITHERSBURG, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) — NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that an abstract containing preliminary data from its first-in-human…
City of Hope will combine its world-leading expertise with NexImmune technology to explore tumor escape mechanisms and to identify unique leukemia stem cell targets for next generation immunotherapeutics GAITHERSBURG, Md.,…
With the start of its second clinical trial, NexImmune expands development of its unique non-genetically engineered T cell immunotherapies across a range of hematologic malignancies GAITHERSBURG, Md., Oct. 06, 2020…
Company is using its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for patients with relapsed and/or refractory hematologic malignancies GAITHERSBURG, Md., Sept. 23, 2020 (GLOBE NEWSWIRE) — NexImmune, a clinical-stage biotechnology company developing…
GAITHERSBURG, MD – June 1, 2020 – NexImmune, a clinical-stage biopharma company advancing a new generation of nanoparticle-based therapies for targeted immune system response, today announced that John Trainer, Chief Financial…
